Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy
Year: 2019
Type: article
Abstract: Diabetic nephropathy (DN) is one of the most common complications of diabetes, and currently the first end-stage renal disease worldwide. New strategies to treat DN using agents that target inflammatory pathways have attracted special interest. Recent pieces of evidences suggest a promising effect of IL-17A, the Th17 effector cytokine. Among experimental DN models, mouse strain BTBR ob/ob (leptin deficiency mutation) develops histological features similar to human DN, which means an opportunity to study mechanisms and novel therapies aimed at DN regression. We found that BTBR ob/ob mice presented renal activation of the factors controlling Th17 differentiation. The presence of IL-17A-expressing cells, mainly CD4 + and γδ lymphocytes, was associated with upregulation of proinflammatory factors, macrophage infiltration and the beginning of renal damage. To study IL-17A involvement in experimental DN pathogenesis, treatment with an IL-17A neutralizing antibody was carried out starting when the renal damage had already appeared. IL-17A blockade ameliorated renal dysfunction and disease progression in BTBR ob/ob mice. These beneficial effects correlated to podocyte number restoration and inhibition of NF-κB/proinflammatory factors linked to a decrease in renal inflammatory-cell infiltration. These data demonstrate that IL-17A takes part in diabetes-mediated renal damage and could be a promising therapeutic target to improve DN.
Source: Kidney International
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,200
Funders: Comunidad de Madrid, Sociedad Española de Nefrología, European Commission, Consejería de Educación, Juventud y Deporte, Comunidad de Madrid, Universidad Austral de Chile, Comisión Nacional de Investigación Científica y Tecnológica, Instituto de Salud Carlos III, Fondo Nacional de Desarrollo Científico y Tecnológico
Awards: G1203152827, G1520406698, G2359567136, G2570692506, G3708003881, G3713805813, Evaluación de nuevas estrategias en el tratamiento de la enfermedad renal del diabétio, G4248028612, Mecanismos moleculares implicados en la fibrosis asociada a la enfermedad renal crónica: búsqueda de nuevas estrategias terapéuticas, G4796369907, G5592101893, G6708836630, G6730178157, G7341080172, G7537002291, Modulación de señales intracelulares y factores de transcripcion en el desarrollo de nuevas terapias para las complicaciones microvasculares de la diabetes, G7759720299, G7812315499, G7837072621, G8359404183, G875433688, Daño cardiovascular asociado a la enfermedad renal crónica. Investigación de mecanismos moleculares y búsqueda de nuevas opciones terapéuticas
OpenAlex ID: W2920992833
